X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (347) 347
humans (343) 343
female (240) 240
antineoplastic combined chemotherapy protocols - therapeutic use (233) 233
carboplatin - administration & dosage (222) 222
paclitaxel - administration & dosage (217) 217
middle aged (192) 192
aged (171) 171
lung neoplasms - drug therapy (169) 169
oncology (152) 152
male (140) 140
carboplatin-paclitaxel (132) 132
carcinoma, non-small-cell lung - drug therapy (129) 129
adult (120) 120
chemotherapy (119) 119
open-label (108) 108
lung neoplasms - pathology (96) 96
1st-line treatment (88) 88
gefitinib (86) 86
neoplasm staging (83) 83
drug administration schedule (82) 82
cisplatin - administration & dosage (73) 73
mutation (68) 68
ovarian neoplasms - drug therapy (68) 68
lung neoplasms - genetics (64) 64
cancer (63) 63
antineoplastic combined chemotherapy protocols - adverse effects (60) 60
carcinoma, non-small-cell lung - pathology (60) 60
combined modality therapy (58) 58
survival rate (58) 58
erlotinib (57) 57
treatment outcome (57) 57
carcinoma, non-small-cell lung - genetics (55) 55
disease-free survival (55) 55
aged, 80 and over (53) 53
retrospective studies (52) 52
lung cancer, non-small cell (49) 49
receptor, epidermal growth factor - genetics (48) 48
lung cancer (47) 47
paclitaxel - adverse effects (45) 45
antineoplastic agents - therapeutic use (44) 44
carboplatin - adverse effects (44) 44
protein kinase inhibitors - therapeutic use (43) 43
adenocarcinoma (41) 41
non-small cell lung cancer (41) 41
care and treatment (40) 40
carboplatin/paclitaxel (39) 39
lung neoplasms - mortality (38) 38
adenocarcinoma - drug therapy (36) 36
epidermal growth factor (36) 36
paclitaxel (36) 36
phase-iii (36) 36
survival (35) 35
cisplatin (34) 34
carcinoma, non-small-cell lung - mortality (33) 33
hematology, oncology and palliative medicine (33) 33
ovarian neoplasms - pathology (33) 33
respiratory system (33) 33
receptor, epidermal growth factor - antagonists & inhibitors (32) 32
bevacizumab (31) 31
acquired-resistance (30) 30
chemotherapy, adjuvant (30) 30
follow-up studies (30) 30
paclitaxel - therapeutic use (30) 30
deoxycytidine - analogs & derivatives (29) 29
phase-iii trial (29) 29
carboplatin - therapeutic use (28) 28
prognosis (28) 28
tyrosine kinase inhibitors (28) 28
antineoplastic agents - administration & dosage (27) 27
remission induction (27) 27
epidermal growth factor receptor (26) 26
multicenter (26) 26
non-small-cell lung cancer (26) 26
nsclc (26) 26
antineoplastic agents, phytogenic - administration & dosage (25) 25
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
carboplatin (25) 25
growth-factor receptor (25) 25
research (25) 25
trial (25) 25
afatinib (24) 24
cell lung-cancer (24) 24
egfr mutations (24) 24
gene-mutations (24) 24
therapy (24) 24
deoxycytidine - administration & dosage (23) 23
egfr (23) 23
genetic aspects (23) 23
medicine & public health (23) 23
ovarian cancer (23) 23
ovarian neoplasms - surgery (23) 23
cancer therapies (22) 22
lung neoplasms - radiotherapy (22) 22
pharmacology & pharmacy (22) 22
quinazolines - therapeutic use (22) 22
respiratory tract diseases (22) 22
antineoplastic agents - adverse effects (21) 21
carcinoma (21) 21
lung neoplasms - surgery (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 141 - 151
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
by Zhou, Caicun and Wu, Y.L and Chen, G and Feng, J and Liu, X.-Q and Wang, C and Zhang, S and Wang, J and Zhou, S and Ren, S and Lu, S and Zhang, L and Hu, C and Hu, C and Luo, Y and Chen, L and Ye, M and Huang, J and Zhi, X and Zhang, Y and Xiu, Q and Ma, J and Zhang, L and You, C
Annals of Oncology, ISSN 0923-7534, 09/2015, Volume 26, Issue 9, pp. 1877 - 1883
Journal Article
by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 830 - 838
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 09/2014, Volume 9, Issue 9, pp. 1345 - 1353
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 06/2019, Volume 37, Issue 16, pp. 1359 - 1359
A healthy 51-year-old woman presented with increasing abdominal and pelvic pain. Computed tomography imaging of the abdomen and pelvis showed an 11.6-cm pelvic... 
PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | INTRAPERITONEAL CHEMOTHERAPY | INTERGROUP TRIAL | ONCOLOGY-GROUP | ONCOLOGY | PRIMARY PERITONEAL CANCER | FALLOPIAN-TUBE | OPEN-LABEL | STAGE-III
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article